Cannacord Genuity, an independent full-services financial services firm, has commenced coverage of Khiron Life Sciences Corp. (TSXV:KHRN), giving it a ‘speculative’ buy rating. Khiron is a vertically-integrated medical cannabis company fully licensed to conduct its core operations in Colombia and, according to Cannacord, is “cultivating a first-mover-advantage” in the most advanced regulatory environment in Latin America.

Cannacord’s coverage outlined by analyst Kimberly Hedlin, and was quoted in part in a recent article on the Globe and Mail, which reviewed input from industry analysts. Hedlin set the target price at $3 per share.

“Following a recent wave of medical cannabis legalizations in Latin America, we believe the market is on the cusp of exponential growth,” said Ms. Hedlin. “In our view, Khiron Life Sciences is positioned to secure a sizeable market share given its first-mover advantage, low-cost operations, robust medical platform and strong management team. We believe the stock provides an attractive entry point with rare exposure to LATAM medical cannabis.”

“Our target reflects an [enterprise value] of $210-million and a 2020 estimated EV-to-EBITDA multiple of 9.2 times,” said the analyst. “We believe this is reasonable in light of recent transactions in the region (which averaged $250-million) and current Canadian trading multiples of 16.5 times. The key risks to our target include Colombian cannabis pricing, receipt of commercial quotas, patient conversion rates and closing of the ILANS acquisition. We believe a ‘Speculative’ classification is appropriate given Khiron’s pre-revenue status.”

To access the full article, click here.

Click here to connect with Khiron Life Sciences Corp. (TSXV:KHRN) for an Investor Presentation.

US-based multi-state operators (MSOs) performed well during Q1, but one fund manager believes that hasn’t been reflected in their share prices.

Keep reading... Show less

 Aion Therapeutic Inc. (CSE: AION) (” Aion Therapeutic ” or the ” Company “) announced today that its proprietary and patented combinatorial mushroom preparations AION F7 and AION F8 (collectively, the ” Aion Mushroom Preparations ” or ” Preparations “) showed high efficacy in killing HER2+ breast cancer cells, ER+PR+ breast cancer cells, and triple-negative breast cancer cells by direct cytotoxicity.

Keep reading... Show less

Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (FSE: L0MA) (“Nextleaf”, “OILS”, or the “Company”) , the world’s most innovative cannabis processor, is pleased to announce that its wholly-owned subsidiary Nextleaf Labs Ltd. (“Nextleaf Labs” or “Labs”) has completed an inaugural bulk CBD distillate delivery to a U.S.-listed, Canadian-based global cannabis company. The Company anticipates similar orders on an ongoing basis.

Keep reading... Show less

The Company Will Tap into Southern Glazer’s Established Distribution Network to Bring Quatreau, its CBD-Infused Sparkling Water, to U.S. Retailers

 Canopy Growth Corporation (“Canopy Growth”) (TSX: WEED) (NASDAQ: CGC), a world-leading diversified cannabis, CBD and vaporization device company, today announced Southern Glazer’s Wine & Spirits (“Southern Glazer’s”), the world’s pre-eminent distributor of beverage alcohol, as the distribution partner for its U.S. portfolio of CBD-infused beverages. This partnership announcement follows the recent launch of Quatreau Canopy’s first line of CBD-infused beverages sold in the U.S market.

Keep reading... Show less

 Canbud Distribution Corporation (CSE: CBDX) (FSE: CD0) (“Canbud” or the “Corporation”) announces its subsidiary Empathy Plant Co. has completed the full development of its vegan multivitamin formula exclusively for women.

Cannot view this image? Visit:
Unique Vegan Women’s Multi-Vitamin with 100% Compostable Packaging

Keep reading... Show less